UOC
IOVA icon

UBS O'Connor’s Iovance Biotherapeutics IOVA Stock Holding History

UBS O'Connor’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-90,000
Closed -$2.25K – 398
2024
Q4 		$2.25K Buy
+90,000
New +$834K ﹤0.01% 414
2024
Q2 		– Sell
-40,000
Closed -$20K – 588
2024
Q1 		$20K Sell
40,000
-290,000
-88% -$3.38M ﹤0.01% 461
2023
Q4 		$900K Buy
330,000
+100,000
+43% +$523K 0.03% 281
2023
Q3 		$190K Buy
+230,000
New +$1.5M ﹤0.01% 450
2023
Q2 		– Sell
-100,000
Closed -$52.5K – 613
2023
Q1 		$52.5K Buy
+100,000
New +$690K ﹤0.01% 546

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

UBS O'Connor's IOVA Position: Q1 2025 in Review

UBS O'Connor sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 149,913 shares — an estimated $1.11M sold.

UBS O'Connor first reported a position in IOVA in Q1 2022 and held it in 10 quarters. The position peaked at $2.84M in Q2 2022. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • UBS O'Connor reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 149,913 Iovance Biotherapeutics shares in Q1 2025, an estimated $1.11M.
  • UBS O'Connor first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 10 quarters.
  • UBS O'Connor's Iovance Biotherapeutics position peaked at $2.84M in Q2 2022.
  • 302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.